A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Bristol-Myers Squibb
Atara Biotherapeutics
AbbVie
miRagen Therapeutics, Inc.
Angimmune LLC
Progen Pharmaceuticals
Morphotek
INSYS Therapeutics Inc